Holiday Notice: Expect delayed shipping. Orders ship 4/6.
FOR RESEARCH PURPOSES ONLY. NOT FOR HUMAN CONSUMPTION.

GLP-1T — Published Research

Reviewed by: Dr. Sarah Chen, PharmD| Last updated: March 16, 2026|For laboratory reference only

← Back to GLP-1T product page

Research Library

Published research on this compound — for educational purposes only

Mechanism as an imbalanced dual agonist

GLP-1T is characterized as an “imbalanced” dual agonist because it displays full agonism at the GIP receptor but biased agonism at the GLP-1 receptor. At the GLP-1R, GLP-1T preferentially activates Gαs-mediated cAMP signaling while exhibiting reduced β-arrestin recruitment compared to native GLP-1. This biased signaling profile results in less receptor internalization and potentially sustained receptor surface availability. The compound’s C-20 fatty diacid moiety enables albumin binding, extending its pharmacokinetic half-life to approximately 5 days. Research compound — not for human use.

Willard FS, et al. JCI Insight. 2020;5(17):e140532. JCI Insight

GLP-1R signaling vs selective GLP-1 agonists

Unlike selective GLP-1 receptor agonists such as GLP-1 S, GLP-1T demonstrates biased agonism at GLP-1R characterized by reduced β-arrestin-1 recruitment. Selective GLP-1 agonists activate both cAMP and β-arrestin pathways with relatively balanced efficacy, leading to robust receptor internalization. GLP-1T’s biased profile — favoring cAMP over β-arrestin — may alter receptor trafficking dynamics. The simultaneous engagement of GIP receptors with full agonism distinguishes GLP-1T’s pharmacological signature from mono-agonist compounds. Research compound — not for human use.

Min Q, et al. Proc Natl Acad Sci USA. 2022;119(34):e2116506119. PNAS

cAMP vs β-arrestin receptor pharmacology

In cell-based assays, GLP-1T activates GIP receptor-mediated cAMP accumulation with potency comparable to native GIP. At the GLP-1 receptor, GLP-1T generates cAMP with approximately 5-fold lower potency than native GLP-1, but displays markedly reduced (>100-fold) β-arrestin-1 and β-arrestin-2 recruitment. This dissociation between G-protein signaling and arrestin recruitment defines GLP-1T as a G-protein-biased agonist at GLP-1R. Research compound — not for human use.

Willard FS, et al. JCI Insight. 2020;5(17):e140532. JCI Insight

Structural basis for dual receptor engagement

GLP-1T is a 39-amino acid linear peptide based on the native GIP sequence with modifications enabling GLP-1R cross-reactivity. Key structural features include an α-aminoisobutyric acid (Aib) substitution at position 2 conferring DPP-4 resistance, and a C-20 fatty diacid moiety conjugated via a linker at lysine-20 enabling non-covalent albumin binding. The exendin-4-derived C-terminal extension (positions 35-39) contributes to GLP-1R engagement. Research compound — not for human use.

Min Q, et al. Proc Natl Acad Sci USA. 2022;119(34):e2116506119. PNAS

Disclaimer: All research citations are provided for educational purposes only. These references describe findings from in vitro and animal model studies. This information does not constitute medical advice and should not be interpreted as endorsement of any specific application.

Reviewed by

Dr. Sarah Chen, PharmD

Research pharmacologist specializing in peptide therapeutics. Reviews published clinical data and pharmacological research for accuracy and completeness.

Editorial Review

Reviewed by Dr. Sarah Chen, PharmD and Dr. James Porter, PhD — Panda Peptides Research Team.

Last reviewed: April 2026.

This content summarizes published peer-reviewed research for educational purposes only. It is not medical advice and does not constitute a recommendation for any specific compound or protocol.